论文部分内容阅读
32磷-玻璃微球（phosphorus－32glassmicrospheres，32P－GMS）是一种新型内放身治疗药物．经对24例晚期肝癌及3例多发性肝血管瘤病人初步临床应用结果表明：粒径45～75μ的32P-GMS也是治疗晚期肝癌安全有效的栓塞材料，肝动脉灌注后无骨髓抑制、肾毒性和明显肝肺分流，肝功能指标多呈一过性改变，但肝吸收放射剂量＞50Gg、微球量＞3g时则出现严重消化道反应和明显肝功能损害，各种术后并发症增多．作者对术后并发症的原因及预防进行了分析探讨．
Phosphorus-32 glass microspheres (32P-GMS) is a new type of medicine for internal body healing. The preliminary clinical results of 24 patients with advanced hepatocellular carcinoma and 3 patients with multiple hemangiomas showed that 32P-GMS with a particle size of 45-75μm was also a safe and effective embolic material for advanced hepatocellular carcinoma. No bone marrow suppression and nephrotoxicity were observed after hepatic artery perfusion. Significant hepatic and pulmonary shunts, liver function indicators were mostly transient changes, but the liver absorbed radiation dose> 50Gg, microspheres> 3g when severe gastrointestinal reactions and significant liver damage, a variety of postoperative complications increased. The author analyzed the causes and prevention of postoperative complications.